Unique ID issued by UMIN | UMIN000022748 |
---|---|
Receipt number | R000026206 |
Scientific Title | Measurement of skin data of hyperpigmentation caused by chemotherapy with pyrimidine fluoride-derived anticancer agent for development of a medical cover foundation |
Date of disclosure of the study information | 2016/06/15 |
Last modified on | 2016/12/15 22:10:51 |
Measurement of skin data of hyperpigmentation caused by chemotherapy with pyrimidine fluoride-derived anticancer agent for development of a medical cover foundation
Measurement of skin data of hyperpigmentation caused by chemotherapy with pyrimidine fluoride-derived anticancer agent
Measurement of skin data of hyperpigmentation caused by chemotherapy with pyrimidine fluoride-derived anticancer agent for development of a medical cover foundation
Measurement of skin data of hyperpigmentation caused by chemotherapy with pyrimidine fluoride-derived anticancer agent
Japan |
gastric cancer, colorectal cancer and esophageal cancer
Gastroenterology | Gastrointestinal surgery | Adult |
Malignancy
NO
The purpose of this study is to measure optical properties of hyperpigmentation caused by chemotherapy with pyrimidine fluoride-derived anticancer agent for development of a medical cover foundation.
Others
To reveal characteristics of optical properties of hyperpigmentation for patients who have strong hyperpigmentation and feel a mental painfulness or distress.
<Assessment by devices>
1) Optical properties (absorption and scattering coefficients)
2) Spectral reflectivity
3) Visia (Facial skin condition)
4) Epidermal and dermal water content
<Self-completed questionnaires>
Appearance-related distress
Observational
20 | years-old | <= |
85 | years-old | >= |
Male and Female
1) Patients who have received pyrimidine fluoride-derived anticancer agent (S-1, capecitabine or 5-FU) more than one month.
2) Patients who have grade 2 "skin hyperpigmentation" in CTCAE Version 4.0.
3) PS of 0 or 1.
4) Written informed consent.
1) Patients who are unable to respond to self-completed questionnaires.
2) Patients who are judged inappropriate for participate in this study by physician.
30
1st name | |
Middle name | |
Last name | Keiko Nozawa |
National Cancer Center Hospital
Appearance Support Center
5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045
03-3547-5201(3015)
knozawa@ncc.go.jp
1st name | |
Middle name | |
Last name | Keiko Nozawa |
National Cancer Center Hospital
Appearance Support Center
5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045
03-3547-5201(3015)
knozawa@ncc.go.jp
National Cancer Center Hospital, Appearance Support Center
Health and Labor Sciences Research Grants 2014
Japanese Governmental office
NO
2016 | Year | 06 | Month | 15 | Day |
Unpublished
Completed
2016 | Year | 05 | Month | 18 | Day |
2016 | Year | 06 | Month | 09 | Day |
2016 | Year | 10 | Month | 18 | Day |
2016 | Year | 10 | Month | 18 | Day |
2017 | Year | 03 | Month | 31 | Day |
This study is to measure optical properties of hyperpigmentation caused by chemotherapy with pyrimidine fluoride-derived anticancer agent.
2016 | Year | 06 | Month | 15 | Day |
2016 | Year | 12 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026206
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |